Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KZR Kezar Life Sciences	$4.47 -0.7%	$4.34	$3.62 ▼ $9.18	$32.68M	0.6	53,936 shs	22,513 shs
NRXP NRx Pharmaceuticals	$3.05 +1.5%	$2.99	$1.10 ▼ $6.01	$52.73M	1.59	420,770 shs	97,128 shs
NTEC Intec Pharma		$13.52	$8.80 ▼ $36.88	$8.65M	0.83	543,436 shs	988,300 shs
RNXT RenovoRx	$1.30	$1.29	$0.75 ▼ $1.69	$47.54M	1.27	102,623 shs	72,954 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KZR Kezar Life Sciences	-2.60%	-1.75%	+3.69%	+8.17%	-30.78%
NRXP NRx Pharmaceuticals	-3.22%	-10.42%	-13.51%	+55.96%	+20.40%
NTEC Intec Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
RNXT RenovoRx	-1.52%	-1.14%	-0.76%	+27.45%	+4.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KZR Kezar Life Sciences	4.1523 of 5 stars	3.2	2.0	0.0	4.6	1.9	3.3	0.6
NRXP NRx Pharmaceuticals	2.7673 of 5 stars	3.6	4.0	0.0	0.0	2.2	0.8	0.6
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	2.2469 of 5 stars	3.5	3.0	0.0	0.0	2.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KZR Kezar Life Sciences	2.33	Hold	$39.50	783.67% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	833.20% Upside
NTEC Intec Pharma	0.00	N/A	N/A	N/A
RNXT RenovoRx	3.00	Buy	$7.25	457.69% Upside

Current Analyst Ratings Breakdown

Latest NTEC, NRXP, KZR, and RNXT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	KZR Kezar Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/5/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $11.50
5/19/2025	RNXT RenovoRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
4/28/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KZR Kezar Life Sciences	$7M	4.67	N/A	N/A	$16.02 per share	0.28
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A	$16.18 per share	N/A
RNXT RenovoRx	$240K	198.10	N/A	N/A	$0.19 per share	6.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KZR Kezar Life Sciences	-$83.74M	-$10.82	N/A	N/A	N/A	N/A	-61.15%	-50.27%	8/12/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.01	N/A	N/A	N/A	N/A	N/A	-355.00%	8/13/2025 (Estimated)
NTEC Intec Pharma	-$14.13M	-$16.32	N/A	N/A	N/A	N/A	-96.37%	-68.87%	N/A
RNXT RenovoRx	-$8.81M	-$0.40	N/A	N/A	N/A	N/A	-119.58%	-88.01%	8/12/2025 (Estimated)

Latest NTEC, NRXP, KZR, and RNXT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	NRXP NRx Pharmaceuticals	-$0.31	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	KZR Kezar Life Sciences	-$2.25	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	RNXT RenovoRx	-$0.08	N/A	N/A	N/A	$0.25 million	N/A
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
5/15/2025	Q1 2025	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.08	$0.23 million	$0.20 million
5/13/2025	Q1 2025	KZR Kezar Life Sciences	-$2.56	-$2.27	+$0.29	-$2.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KZR Kezar Life Sciences	0.04	7.09	7.09
NRXP NRx Pharmaceuticals	N/A	0.22	0.22
NTEC Intec Pharma	N/A	2.34	2.34
RNXT RenovoRx	N/A	9.07	9.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KZR Kezar Life Sciences	67.90%
NRXP NRx Pharmaceuticals	4.27%
NTEC Intec Pharma	22.37%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
KZR Kezar Life Sciences	10.40%
NRXP NRx Pharmaceuticals	19.00%
NTEC Intec Pharma	3.30%
RNXT RenovoRx	9.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KZR Kezar Life Sciences	60	7.31 million	6.55 million	Not Optionable
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable
NTEC Intec Pharma	40	898,000	N/A	Optionable
RNXT RenovoRx	6	36.57 million	33.23 million	Not Optionable

NTEC, NRXP, KZR, and RNXT Headlines

Recent News About These Companies

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

July 14 at 9:12 AM | businesswire.com

Insider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys 21,000 Shares of Stock

June 10, 2025 | insidertrades.com

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

June 6, 2025 | finance.yahoo.com

Ascendiant Capital relève l’objectif de cours de l’action RenovoRx à 11,50€

June 5, 2025 | fr.investing.com

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations

May 17, 2025 | investing.com

RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...

May 16, 2025 | finance.yahoo.com

Le BPA de RenovoRx a dépassé les attentes, le CA en dessous des prévisions

May 15, 2025 | fr.investing.com

Transcription des résultats : le chiffre d’affaires de RenovoRx au T1 2025 dépasse les attentes

May 15, 2025 | fr.investing.com

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

May 15, 2025 | zacks.com

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025 | businesswire.com

Earnings Preview For RenovoRx

May 14, 2025 | benzinga.com

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025 | finance.yahoo.com

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025 | finance.yahoo.com

Johns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III TIGeR-PaC en cours de RenovoRx

April 30, 2025 | zonebourse.comZ

Johns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III en cours de Renovorx sur le Tiger-Pac

April 29, 2025 | zonebourse.comZ

Johns Hopkins rejoint l’essai TIGeR-PaC de RenovoRx sur le cancer du pancréas

April 29, 2025 | fr.investing.com

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

April 29, 2025 | finance.yahoo.com

RenovoRx ramps up production of FDA-cleared RenovoCath

April 18, 2025 | uk.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Chime Financial: Analysts Ring In—And It’s a Buy
By Thomas Hughes | July 9, 2025
View Chime Financial: Analysts Ring In—And It’s a Buy

NTEC, NRXP, KZR, and RNXT Company Descriptions

Kezar Life Sciences NASDAQ:KZR

$4.47 -0.03 (-0.67%)

As of 02:52 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

NRx Pharmaceuticals NASDAQ:NRXP

$3.05 +0.04 (+1.46%)

As of 02:53 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Intec Pharma NASDAQ:NTEC

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

RenovoRx NASDAQ:RNXT

$1.30 0.00 (0.00%)

As of 02:52 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time